NZ512822A - The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation - Google Patents

The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Info

Publication number
NZ512822A
NZ512822A NZ512822A NZ51282200A NZ512822A NZ 512822 A NZ512822 A NZ 512822A NZ 512822 A NZ512822 A NZ 512822A NZ 51282200 A NZ51282200 A NZ 51282200A NZ 512822 A NZ512822 A NZ 512822A
Authority
NZ
New Zealand
Prior art keywords
alkyl
alkylamino
phenyl
crc4
flavopiridol
Prior art date
Application number
NZ512822A
Other languages
English (en)
Inventor
Winston Campbell Patterson
Jennifer A Dumont
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NZ512822A publication Critical patent/NZ512822A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ512822A 1999-02-01 2000-01-18 The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation NZ512822A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24338099A 1999-02-01 1999-02-01
US09/468,665 US6399633B1 (en) 1999-02-01 1999-12-21 Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
PCT/US2000/001104 WO2000044362A2 (en) 1999-02-01 2000-01-18 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Publications (1)

Publication Number Publication Date
NZ512822A true NZ512822A (en) 2005-01-28

Family

ID=22918541

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512822A NZ512822A (en) 1999-02-01 2000-01-18 The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Country Status (38)

Country Link
US (1) US6399633B1 (enExample)
EP (1) EP1150746B1 (enExample)
JP (1) JP4755759B2 (enExample)
KR (1) KR100793047B1 (enExample)
CN (1) CN1219556C (enExample)
AP (1) AP1469A (enExample)
AR (1) AR042569A1 (enExample)
AT (1) ATE275428T1 (enExample)
AU (1) AU777368B2 (enExample)
BG (1) BG65151B1 (enExample)
BR (1) BR0007911A (enExample)
CA (1) CA2360668C (enExample)
CR (1) CR6448A (enExample)
CZ (1) CZ300395B6 (enExample)
DE (1) DE60013555T2 (enExample)
DK (1) DK1150746T3 (enExample)
EA (1) EA004786B1 (enExample)
EE (1) EE04851B1 (enExample)
ES (1) ES2226792T3 (enExample)
HK (1) HK1042445B (enExample)
HR (1) HRP20010521A2 (enExample)
HU (1) HU229263B1 (enExample)
ID (1) ID30180A (enExample)
IL (1) IL144668A (enExample)
ME (1) MEP10508A (enExample)
NO (1) NO330512B1 (enExample)
NZ (1) NZ512822A (enExample)
OA (1) OA11755A (enExample)
PL (1) PL197693B1 (enExample)
PT (1) PT1150746E (enExample)
RS (1) RS50242B (enExample)
SI (1) SI1150746T1 (enExample)
SK (1) SK286747B6 (enExample)
TR (1) TR200102223T2 (enExample)
TW (1) TWI273907B (enExample)
UA (1) UA73110C2 (enExample)
WO (1) WO2000044362A2 (enExample)
ZA (1) ZA200105596B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
WO2003088903A2 (en) * 2002-04-17 2003-10-30 Cytokinetics, Inc. Compounds, compositions, and methods
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
AU2003280090A1 (en) * 2002-06-28 2004-01-19 Baylor College Of Medicine Modulators of cdk9 as a therapeutic target in cardiac hypertrophy
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
JP2008546805A (ja) 2005-06-23 2008-12-25 メディミューン，エルエルシー 最適な凝集および断片化プロフィールを有する抗体製剤
US20100068238A1 (en) * 2005-07-15 2010-03-18 Nandkishore Managoli Implantable Medical Devices Comprising a Flavonoid or Derivative Thereof for Prevention of Restenosis
JP2008255008A (ja) * 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
CA2617213C (en) * 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
NZ596091A (en) 2006-08-28 2012-07-27 Jolla Inst Allergy Immunolog Antagonistic human light-specific human monoclonal antibodies
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
WO2009158404A1 (en) 2008-06-26 2009-12-30 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101803259B1 (ko) 2009-03-18 2017-11-30 리스버로직스 코퍼레이션 신규한 소염제
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
EP2593099A1 (en) 2010-07-12 2013-05-22 DKFZ Deutsches Krebsforschungszentrum Wogonin for the prevention and therapy of cardiac hypertrophy
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
LT3041507T (lt) 2013-08-26 2021-08-25 Biontech Research And Development, Inc. Nukleorūgštys, koduojančios antikūnus prieš sialil-lewis a
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA3121083C (en) 2014-06-04 2023-08-15 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside gd2
SI3333191T1 (sl) 2014-12-11 2021-03-31 Pierre Fabre Medicament Proti C10ORF54 protitelesa in uporaba le-teh
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
MX2017013383A (es) 2015-04-20 2017-12-07 Tolero Pharmaceuticals Inc Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
PL3298021T3 (pl) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Proleki alvocidibu o zwiększonej biodostępności
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
WO2017096051A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR102466192B1 (ko) 2016-08-23 2022-11-14 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포성 암종의 치료를 위한 조합 요법
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
RU2764724C2 (ru) 2017-03-16 2022-01-19 ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. Комбинированная терапия для лечения рака молочной железы
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
US12215151B2 (en) 2017-05-31 2025-02-04 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
JP7256796B2 (ja) 2017-10-13 2023-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
AU2019391097B2 (en) 2018-12-04 2025-07-03 Sumitomo Pharma America, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN113559244B (zh) * 2021-08-02 2023-12-26 华中科技大学同济医学院附属协和医院 Ctrp13脂肪因子的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (enExample) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation

Also Published As

Publication number Publication date
PT1150746E (pt) 2004-12-31
ES2226792T3 (es) 2005-04-01
CR6448A (es) 2004-03-17
US6399633B1 (en) 2002-06-04
JP4755759B2 (ja) 2011-08-24
AP2001002218A0 (en) 2001-09-30
CN1338958A (zh) 2002-03-06
CA2360668A1 (en) 2000-08-03
TR200102223T2 (tr) 2004-12-21
WO2000044362A2 (en) 2000-08-03
JP2002535356A (ja) 2002-10-22
CZ20012804A3 (cs) 2002-08-14
RS50242B (sr) 2009-07-15
OA11755A (en) 2005-07-19
AP1469A (en) 2005-09-26
CZ300395B6 (cs) 2009-05-06
ZA200105596B (en) 2002-10-07
PL197693B1 (pl) 2008-04-30
HU229263B1 (en) 2013-10-28
PL350735A1 (en) 2003-01-27
IL144668A0 (en) 2002-05-23
ID30180A (id) 2001-11-08
SK286747B6 (sk) 2009-04-06
DE60013555D1 (de) 2004-10-14
NO330512B1 (no) 2011-05-09
EE200100385A (et) 2002-12-16
EP1150746A2 (en) 2001-11-07
TWI273907B (en) 2007-02-21
KR100793047B1 (ko) 2008-01-10
YU54401A (sh) 2004-05-12
HRP20010521A2 (en) 2002-08-31
BR0007911A (pt) 2001-10-16
NO20013335D0 (no) 2001-07-05
WO2000044362A3 (en) 2001-04-05
SI1150746T1 (en) 2005-02-28
ATE275428T1 (de) 2004-09-15
EP1150746B1 (en) 2004-09-08
NO20013335L (no) 2001-09-25
BG65151B1 (bg) 2007-04-30
DK1150746T3 (da) 2005-01-10
HUP0200804A3 (en) 2004-03-29
HK1042445B (zh) 2006-01-13
KR20010093309A (ko) 2001-10-27
MEP10508A (en) 2010-06-10
UA73110C2 (en) 2005-06-15
IL144668A (en) 2005-06-19
CN1219556C (zh) 2005-09-21
EA200100742A1 (ru) 2001-12-24
BG105751A (en) 2002-02-28
AU777368B2 (en) 2004-10-14
CA2360668C (en) 2009-03-17
EA004786B1 (ru) 2004-08-26
HUP0200804A2 (hu) 2002-12-28
AR042569A1 (es) 2005-06-29
HK1042445A1 (en) 2002-08-16
AU3209800A (en) 2000-08-18
DE60013555T2 (de) 2005-09-29
EE04851B1 (et) 2007-06-15
SK10862001A3 (sk) 2002-07-02

Similar Documents

Publication Publication Date Title
CA2360668C (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
Kwak et al. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways
Hu et al. Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death
JP5435946B2 (ja) 疾患を処置するためのヘッジホッグ経路アンタゴニスト
US20140005127A1 (en) Methods of treating muscular wasting diseases using nf-kb activation inhibitors
Zhu et al. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss
Cammalleri et al. The urokinase‐type plasminogen activator system as drug target in retinitis pigmentosa: New pre‐clinical evidence in the rd10 mouse model
Zhang et al. Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease
Kikuchi et al. p27kip1 Antisense-induced proliferative activity of rat corneal endothelial cells
MXPA01007278A (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
US6495588B2 (en) Scytonemin and methods of using thereof
Zhang Yaxuan Zhang, Yuan Yuan, Jiawei Zhang, Yao Zhao, Yueqi Zhang and Jianliang Fu
Guo Regulation of Ribosome Biogenesis and Skeletal Muscle Size Control
JP2023081768A (ja) 脂肪肝治療剤、医薬組成物、治療方法、及びスクリーニング方法
WO2006124727A2 (en) Compositions and methods useful in preventing cardiac hypertrophy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired